Kyowa Kirin Co., Ltd. (4151.T) is currently considered halal (Sharia-compliant), per In-house ratio engine (last assessed 2026-08-28). See the full ratio breakdown and business-activity screen below for the reasoning.
Computed from published company financials, balance sheet as of 2025-12-31. 4151.T files no SEC reports, so these ratios come from the issuer's own published statements rather than XBRL.
Business activity: cleared (no excluded categories detected)
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing investments | 17.39% | 30.00% | Pass |
| Non-permissible income | 0.95% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Interest-bearing investments | 19.84% | 33.00% | Pass |
| Non-liquid assets | 63.80% | at least 20.00% | Pass |
| Non-permissible income | 0.95% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 19.84% | 33.33% | Pass |
| Accounts receivable | 36.20% | 33.33% | Fail |
| Non-permissible income | 0.95% | 5.00% | Pass |
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 19.84% | 33.33% | Pass |
| Accounts receivable | 36.20% | 50.00% | Pass |
| Non-permissible income | 0.95% | 5.00% | Pass |
Scored against a trailing-average market cap (24-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 15.72% | 33.00% | Pass |
| Accounts receivable | 12.96% | 33.00% | Pass |
| Non-permissible income | 0.95% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 15.45% | 49.00% | Pass |
| Accounts receivable | 12.73% | 49.00% | Pass |
| Non-permissible income | 0.95% | 5.00% | Pass |
Scored against a trailing-average market cap (36-month), share-weighted by the issuer's own reported share counts — not today's market cap.
| Ratio | Value | Threshold | Result |
|---|---|---|---|
| Cash + interest-bearing securities | 15.45% | 33.33% | Pass |
| Accounts receivable | 28.18% | 49.00% | Pass |
| Non-permissible income | 0.95% | 5.00% | Pass |
Research only, not investment advice. Thresholds are each standard-setter's published limits; a ratio marked “at least” is a floor, not a ceiling.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 27.40 | BUY |
| Stochastic %K (14) | 6.57 | BUY |
| CCI (20) | -163.35 | BUY |
| Williams %R (14) | -93.43 | BUY |
| MACD (12,26,9) | -41.72 | SELL |
| ROC (10) | -17.72 | SELL |
| Momentum (10) | -472.00 | SELL |
| EMA (10) | 2352.67 | SELL |
| SMA (10) | 2391.30 | SELL |
| EMA (20) | 2438.42 | SELL |
| SMA (20) | 2490.45 | SELL |
| EMA (30) | 2476.31 | SELL |
| SMA (30) | 2506.42 | SELL |
| EMA (50) | 2501.24 | SELL |
| SMA (50) | 2566.55 | SELL |
| EMA (100) | 2496.57 | SELL |
| SMA (100) | 2476.24 | SELL |
| EMA (200) | 2468.54 | SELL |
| SMA (200) | 2484.53 | SELL |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
Healthcare · Drug Manufacturers - Specialty & Generic
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia. It has a partnership with La Jolla Institute for Immunology for research in disease areas; AstraZeneca for severe asthma treatment; and AMGEN for therapeutic drugs development. The company was formerly known as Kyowa Hakko Kirin Co., Ltd. and changed its name to Kyowa Kirin Co., Ltd. in July 2019. Kyowa Kirin Co., Ltd. was incorporated in 1949 and is headquartered in Chiyoda, Japan. The company operates as a subsidiary of Kirin Holdings Company, Limited.
Background via Yahoo Finance — informational, not part of the verdict.
Research only, not the primary verdict above — SEC EDGAR (the source for the main in-house research card, if shown) has no data for this symbol, so this is computed from a real, country-specific filing instead. Business-activity screening isn't part of this check.
Based on the filing period ending 2025-12-31, figures in JPY.
Peer movement computing — it will appear here on its own.
NO DATA 0 buys · 0 sells
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.